SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apple shares experienced high volatility during a product launch event that introduced the iPhone Duo, the company's first foldable smartphone, and an updated Pro series lineup. While some traders expressed skepticism regarding the high price point of the foldable device and broader innovation, others remained bullish, focusing on potential revenue growth and the stock's resilience during the announcement.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is trending following a record-breaking second-quarter operating income and a significant $1 million share purchase by Director Lawrence Cheng. While some investors are bullish on the company's improved profitability and insider confidence, others express frustration over declining revenue and the lack of communication regarding company strategy.

AeroVironment, Inc. is a defense technology company delivering integrated capabilities across air, land, sea, space, and cyber. The company develops and deploys autonomous systems, loitering munitions, counter-UAS technologies, space-based platforms, directed energy systems, and cyber and electronic warfare capabilities-built to meet the mission needs of today’s warfighter and tomorrow’s conflicts. At the core of these technologies lies AV_Halo, a modular, mission-ready suite of AI-powered software tools that empowers warfighters and enables full-battlefield dominance: detect, decide, deliver. With a national manufacturing footprint and a deep innovation pipeline, AV delivers proven systems and future-defining capabilities at speed, scale, and operational relevance. The company was founded by Paul B. MacCready, Jr. in July 1971 and is headquartered in Arlington, VA.

AeroVironment Inc.

AeroVironment is trending following a significant U.S. Army contract award for directed-energy counter-drone systems, which investors view as a major catalyst for long-term growth and defense sector dominance. While community sentiment is heavily bullish, some traders are debating the stock's volatility and the impact of the contract on short-term valuation.

SK hynix, Inc. engages in the design, manufacture, and sale of semiconductor products. Its products include dynamic random access memory, not-AND flash memory, and multi-chip package. The company was founded on October 15, 1949 and is headquartered in Icheon, South Korea.

SK Hynix Inc - ADR

SK Hynix is trending following the announcement of a massive, multi-billion dollar share repurchase and cancellation program aimed at stabilizing its share price. Investors are largely reacting to the company's commitment to return capital to shareholders, fueling bullish sentiment despite recent broader market volatility in the semiconductor sector.

Vertiv Holdings Co. engages in the design, manufacture, and service of critical digital infrastructure technology for data centers, communication networks, and commercial and industrial environments. The firm also offers power management products, switchgear and busbar products, thermal management products, integrated rack systems, modular solutions, and management systems for monitoring and controlling digital infrastructure. It operates through the following geographical segments: Americas, Asia Pacific, and Europe, Middle East, and Africa (EMEA). The Americas segment includes products and services sold for applications within the data center, communication networks and commercial and industrial markets in North America and Latin America. The Asia Pacific segment consists of products and services sold for applications within the data center, communication networks and commercial and industrial markets throughout Greater China, Asia, and India. The EMEA segment focuses on products and services sold for applications within the data center, communication networks, and commercial and industrial markets in Europe, Middle East, and Africa. The company was founded in 1946 and is headquartered in Westerville, OH.

Vertiv Holdings Co - Ordinary Shares - Class A

Vertiv Holdings Co

Vertiv is experiencing a sharp sell-off as traders react to a revenue miss in the company's latest earnings report, despite an earnings beat and an upward revision to its full-year guidance. While some investors are expressing frustration over the volatility, others are viewing the pullback as an oversold buying opportunity given the company's continued role in the AI data center cooling and power infrastructure buildout.

ServiceTitan, Inc. engages in the collection of field service activities required to install, maintain, and service the infrastructure and systems of residences and commercial buildings. The company was founded by Ara Mahdessian and Vahe Kuzoyan on June 8, 2008 and is headquartered in Glendale, CA.

ServiceTitan Inc. - Ordinary Shares - Class A

ServiceTitan 

ServiceTitan shares fell sharply after the company issued third-quarter revenue guidance that missed analyst expectations, overshadowing a second-quarter earnings and revenue beat. Investors also reacted negatively to a management transition involving the departure of the Chief Revenue Officer.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending after reporting clinical trial results for its sonelokimab therapy in psoriatic arthritis that met primary endpoints but underwhelmed investors looking for blowout efficacy. Traders are debating the company's long-term commercialization strategy, with many expressing frustration over recent dilutive share offerings and lack of clear buyout signals.

Norwegian Cruise Line Holdings Ltd. engages in the provision of cruise travel services. It offers cruise experiences for travelers with itineraries in Europe, Asia, Australia, New Zealand, South America, Africa, Canada, Bermuda, Caribbean, Alaska and Hawaii. Its brands include Norwegian Cruise Line, Oceania Cruises, and Regent Seven Seas Cruises. The company was founded in 1966 and is headquartered in Miami, FL.

Norwegian Cruise Line Holdings Ltd

Norwegian Cruise Line Holdings is trending due to persistent volatility driven by fluctuating oil prices and geopolitical tensions, which have weighed heavily on sentiment despite solid cruise demand. Traders remain divided between those viewing the current price as a buying opportunity, citing institutional insider accumulation, and those expressing frustration over perceived market manipulation and the stock's failure to maintain upward momentum.

Ford Motor Co. engages in the manufacture, distribution, and sale of automobiles. It operates through the following segments: Ford Blue, Ford Model E, Ford Pro, Ford Credit, and Corporate Other. The Ford Blue, Ford Model E, and Ford Pro segment includes the sale of Ford and Lincoln vehicles, service parts, and accessories, together with the associated costs to develop, manufacture, distribute, and service the vehicles, parts, and accessories. The Ford Credit segment consists of the Ford Credit business on a consolidated basis, which is primarily vehicle-related financing and leasing activities. The Corporate Other segment refers to corporate governance expenses, past service pension and OPEB income and expense, interest income and gains and losses from cash, cash equivalents, and marketable securities, and foreign exchange derivatives gains, and losses associated with intercompany lending. The company was founded by Henry Ford on June 16, 1903 and is headquartered in Dearborn, MI.

Ford Motor Co.

Ford Motor Co

Ford is trending as investors react to the company's recent earnings report, with sentiment divided between the positive impact of raised guidance and concerns over margin compression and sales declines. Additionally, ongoing uncertainty surrounding potential U.S. tariffs on Canadian auto imports continues to weigh on investor outlook and fuel volatility.

Opus Genetics, Inc. engages in the research and development of ophthalmic biopharmaceutical products. It focuses on developing and commercializing therapies for the treatment of several eye disorders. The company was founded by Mina Patel Soouch and Alan R. Meyer in February 2018 and is headquartered in Durham, NC.

Opus Genetics Inc.

Opus Genetics (IRD) is trending following positive Phase 1/2 clinical trial data for its experimental OPGx-BEST1 gene therapy, which demonstrated meaningful vision improvement in patients. While investors are bullish on the company's clinical progress and path toward potential Phase 3 trials in 2027, some traders express caution regarding the company's financial position and the long-term outlook for clinical development.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$SLS $ABBV $BMY  
 
72nd Event Dec 26th 2025  
+4.5 Months  
78th Event May 11th 2026  
4.5 Months for the Last 6 Events / 1 Event every 22.67 Days 
 
Its  Now Been 121 Days Since the 78th Event .... 
 
ANY DAY NOW  - We Will See the 80th Event and Share Price Launch. 
 
GPs is worth every nickel of $50B to big Pharma - this market rigged $14 /$2.8B Mcap will be a $28B Mcap / $140 Per Share and Climbing ... the instant the P3 Results are Announced.  
MARKTHISPOST

Juhana Tikkanen

Robert Brooks

5,500% ROI this quarter

midwestmoneymom

F. S. Fetchet

Jason McClain

$SLS The SLS Chart tells what happened and what will happen.  
  
80th Event --- is coming, any day now - it is inevitable.  
121 Days since the 78th May 11th ---     
   
Dec 2024 - 60th EVENT   
Dec 2025 - 72nd EVENT 12 events in 12 months   
May 2026 - 78th EVENT 6 events in 6 months    
• 18 Events in 18 Months    
and its been 121 Days since the 78th   
3 months 25 days  
  
wait until the Imminent 80th event pr and buy in for $25 - before this runs to $150 on the Gps P3 Top line:   
   
• GPs MOS 36 months CR2 AML vs BAT &lt; 10 months   
   
$MRNA Added $40B in a Day Based on a 13.7 Month MOS for 2L Melanoma  
• this Rigged  $13.90 Share Price will be $139 and running as the market realizes GPs true value - treating 50,000 AML Remission Patients each year - and generating Tens of Billions of Dollars in Real Revenue.  
  
//

StockTwits Web

SELLAS Life Sciences Group Inc

Moderna Inc

$SLS  
$MRNA added $40B in a day when its P3 Cancer vaccine results were announced: 13.7 month MOS vs 7 w soc. 
 
Gps P3 results &gt;34 months vs BAT &lt; 10 months are Imminent. 
 
This rigged $2.8B SLS Mcap is about to be a $28B mcap and More.

$SLS The Future is Inevitable. Be Holding. 
 
121 Days Since the 78th Event --- 80th and Share Price Launch IMMINENT.

Abbvie Inc

Bristol-Myers Squibb Co.

  
 
72nd Event Dec 26th 2025  
+4.5 Months  
78th Event May 11th 2026  
4.5 Months for the Last 6 Events / 1 Event every 22.67 Days 
 
Its  Now Been 121 Days Since the 78th Event .... 
 
ANY DAY NOW  - We Will See the 80th Event and Share Price Launch. 
 
GPs is worth every nickel of $50B to big Pharma - this market rigged $14 /$2.8B Mcap will be a $28B Mcap / $140 Per Share and Climbing ... the instant the P3 Results are Announced.  
MARKTHISPOST

@55X_ROI_Q1_2026 I appreciate the enthusiasm—I’m bullish on SLS too and hold a significant position. That said, I’ve noticed similar posts with ambitious price targets appearing daily across SLS and other boards, including ABVX. I’d love to see more of the research behind your conviction: factual updates, credible sources, and a balanced discussion of the upside and risks. Repeating big price predictions can unintentionally come across as promoting the stock rather than informing investors, even when the enthusiasm is genuine. Sharing solid due diligence would add much more value and help people make informed decisions. Let’s let the facts build the confidence, rather than the price predictions

 I appreciate the enthusiasm—I’m bullish on SLS too and hold a significant position. That said, I’ve noticed similar posts with ambitious price targets appearing daily across SLS and other boards, including ABVX. I’d love to see more of the research behind your conviction: factual updates, credible sources, and a balanced discussion of the upside and risks. Repeating big price predictions can unintentionally come across as promoting the stock rather than informing investors, even when the enthusiasm is genuine. Sharing solid due diligence would add much more value and help people make informed decisions. Let’s let the facts build the confidence, rather than the price predictions

Davinder Sekhon

@55X_ROI_Q1_2026 Major High-Value Acquisitions (2016–2026) 
 
Merck &amp; Co. acquires Prometheus Biosciences (2023): $10.8 billion to expand immunology pipelines. 
 
Pfizer acquires Seagen (2023): $43 B to lead in antibody-drug conjugates for cancer. 
 
Bristol Myers Squibb acquires Celgene (2019): $74 B, one of the largest healthcare deals ever, adding major oncology and immunology blockbusters. 
 
AbbVie acquires Allergan (2019): $63 B to diversify revenue with Botox and therapeutic portfolios. 
 
AstraZeneca acquires Alexion Pharmaceuticals (2020): $39 B to expand into rare diseases and immunology. 
 
Amgen acquires Horizon Therapeutics (2022): $27.8 B for rare disease treatments. 
 
Gilead Sciences acquires Immunomedics (2020): $21 B to bolster targeted cancer therapies. 
 
Gilead Sciences acquires Kite Pharma (2017): $11.9 B to gain cell therapy and CAR-T capabilities. 
 
Merck KGaA acquires Bio-Techne (2026): $11.3 B. 
 
AbbVie acquires Apogee Therapeutics (2026): $10.9 billion for clinical-stage immunology programs

 Major High-Value Acquisitions (2016–2026) 
 
Merck & Co. acquires Prometheus Biosciences (2023): $10.8 billion to expand immunology pipelines. 
 
Pfizer acquires Seagen (2023): $43 B to lead in antibody-drug conjugates for cancer. 
 
Bristol Myers Squibb acquires Celgene (2019): $74 B, one of the largest healthcare deals ever, adding major oncology and immunology blockbusters. 
 
AbbVie acquires Allergan (2019): $63 B to diversify revenue with Botox and therapeutic portfolios. 
 
AstraZeneca acquires Alexion Pharmaceuticals (2020): $39 B to expand into rare diseases and immunology. 
 
Amgen acquires Horizon Therapeutics (2022): $27.8 B for rare disease treatments. 
 
Gilead Sciences acquires Immunomedics (2020): $21 B to bolster targeted cancer therapies. 
 
Gilead Sciences acquires Kite Pharma (2017): $11.9 B to gain cell therapy and CAR-T capabilities. 
 
Merck KGaA acquires Bio-Techne (2026): $11.3 B. 
 
AbbVie acquires Apogee Therapeutics (2026): $10.9 billion for clinical-stage immunology programs

John

@55X_ROI_Q1_2026 I would be love $50 B but would be very happy with anything north of $30 B.  30 billion would be 10x of where we are today and anything over $140 is great.

$SLS Max Value...@arreyda ... 
I bought a ton a .57... and a ton more ... higher.  
I expect Max Value ... just like ANGIE STATED ...  
 
Gps will generate $10B in actual revenue -- that is the multiple derivative JUST FOR GPS in AML&gt; $50B to Big Pharma 
 
+ add in 1M WT1 + Patients Diagnosed each year. 
$300B TAM ...  
+ 009 Value is  already $50/$60PER share...  
 
SLS is  the most manipulated Undervalued Equity in the Market.

 I would be love $50 B but would be very happy with anything north of $30 B.  30 billion would be 10x of where we are today and anything over $140 is great.